CLINICAL CASE SEMINAR

Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor

PATRICIA L. BRUBAKER, DANIEL J. DRUCKER, SYLVIA L. ASA, CAROL SWALLOW, MARK REDSTON, AND GORDON R. GREENBERG

Departments of Physiology (P.L.B.), Medicine (P.L.B., D.J.D., G.R.G.), Lab Medicine and Pathobiology (S.L.A., M.R.), Surgery (C.S.), and the Banting and Best Diabetes Centre (D.J.D.), University of Toronto, Toronto, Ontario M5S 1A8, Canada

Neuroendocrine tumors overexpressing the proglucagon-derived peptides have been associated with severe constipation. The relationship between two of the intestinal proglucagon-derived peptides, glucagon-like peptide (GLP)-1 and -2, and delayed gastrointestinal transit, was characterized in a patient with a neuroendocrine proglucagon-derived peptide tumor. A 60-yr-old female presented with intractable constipation and intermittent vomiting. Gastric, oral-ileal and colonic transit times, and plasma hormone levels were determined before tumor resection. Expression of the proglucagon-derived peptides by the tumor was determined by immunohistochemistry, Northern blot analysis, HPLC, and RIA. Oral-cecal transit was more than 3 h, and a barium follow-through study showed dilated and thickened folds with most of the barium concentrated in the ileum at 24 h; residual barium was identified in the colon at 14 d post ingestion. Circulating levels of GLP-1 and -2 were 300- to 400-fold elevated compared with levels in normal human subjects. Normal bowel function was restored by tumor resection. Consistent with the elevated plasma hormone levels, the tumor was found to express the proglucagon gene, and immunoreactive GLP-1 and -2 were detected by both immunohistochemistry and RIA. Overexpression of glucagon-like peptide-1 and -2 is associated with markedly prolonged gastrointestinal transit in humans. These findings are consistent with a role for these peptides in the regulation of gastrointestinal motility. (J Clin Endocrinol Metab 87: 3078–3083, 2002)

THE ILEAL BRAKE is a neurohormonal feedback mechanism that delays gastric and intestinal transit time, thereby enhancing nutrient digestion and absorption in the proximal small intestine and preventing nutrient overflow into the distal gut (1). A number of gut peptides have been identified as possible effectors of intestinal motility (2), including the glucagon-like peptides (GLP), GLP-1 and GLP-2, and peptide YY (PYY). All three of these hormones are synthesized in the intestinal L cell from their prohormone precursors, proglucagon and proPYY, respectively (3, 4). Ingestion of nutrients, and of fat and carbohydrates in particular, increases the release of GLP-1, GLP-2, and PYY into the circulation (5–8). Infusion of GLP-1 and GLP-2 has also been shown to prolong the rate of gastric emptying and delay intestinal transit time (9–11). Additionally, antagonism of the GLP-1 receptor increases gastric emptying, further suggesting a physiological role for GLP-1 in the ileal brake (12, 13). Injection of PYY also potently inhibits gastrointestinal motility, whereas immunoneutralization of PYY causes acceleration of intestinal transit (7, 14, 15). Other biological actions of these peptides include stimulation of glucose-dependent insulin secretion and inhibition of glucagon release by GLP-1 (16–18), and stimulation of intestinal growth by GLP-2 (17–19).

An association between overexpression of the GLPs and the ileal brake was first made in a patient with severe constipation and the presence of an ectopic enteroglucagon-producing tumor (20, 21). It is now recognized that enteroglucagon is comprised of two proglucagon-derived peptides, glicentin and oxyntomodulin, and that these peptides are co-synthesized with GLP-1 and GLP-2 in the intestinal L cell (Fig. 1). However, the existence and functions of GLP-1 and GLP-2 were not known at the time of this original case report. In the present report, we describe the presence of markedly delayed gastrointestinal transit in a patient with an ectopic tumor producing both GLP-1 and GLP-2.

Patients and Methods

Patient

A 60-yr-old white female presented for assessment of progressive intractable constipation of 5 yr duration. Bowel actions occurred every 10–14 d but only with ingestion of magnesium citrate or after an enema. The patient also experienced vomiting of solid food about three times weekly, but her weight remained stable. Physical examination was unremarkable. Investigations after referral, undertaken after the patient provided informed consent, included normal hematology, biochemistry, and a normal colonoscopy with the exception of a few diverticula in the sigmoid colon. A barium upper gastrointestinal and follow-through study showed dilated and thickened mucosal folds; progression of the

Abbreviations: GLI, Glucagon-like immunoreactivity; GLP, glucagon-like peptide; GLUTag, glucagon-SV40-large T antigen cells; IRG, immunoreactive glucagon; PYY, peptide YY; STC-1, secretin tumor cells.
barium column was also delayed and at 24 h post ingestion most of the barium remained concentrated in the ileum with residual barium identified in the colon at 14 d post ingestion. A lactulose breath hydrogen study indicated delayed oral-cecal transit with the breath hydrogen peak observed more than 3 h post ingestion. A 99m technetium-sulfur colloid gastric emptying study showed more than 20% residual activity after 4 h. The patient refused a gastroscopy. A diagnosis of pseudo-obstruction was made; treatment with cisapride (40 mg three times daily) and subsequently clarithromycin (250 mg three times daily) was without effect.

To further characterize the constipation, investigations after referral included a colonoscopy, which was normal with the exception of sigmoid diverticula; the cecum and ileum were not visualized because of the presence of impacted stool, notwithstanding extensive preparation. Biopsies of the colon showed crypts with epithelial atypia, mild crypt distortion, and moderate fibrosis of the lamina propria. Crypt epithelial atypia consisted of some nuclear enlargement with mild stratification and mucous depletion; there was no evidence of crypt budding or proliferation. The epithelial changes showed no evidence of dysplasia and were consistent with reactive changes occurring secondary to chronic colonic stasis.

An abdominal CT scan identified a 6.5 × 5.5 × 7.3 cm solid mass in the left abdomen, just to the left of the aorta with the center at the level of the inferior pole of the left kidney; the liver was normal. An indium111-labeled octreotide scan demonstrated a large focus of activity corresponding to the lesion identified on the CT scan; there was no evidence of metastasis. A needle aspirate of the mass was consistent with a neuroendocrine neoplasm. The patient underwent resection of the tumor with an uneventful postoperative course. The bowel habit normalized after surgery and at 2 yr follow-up, the patient remained asymptomatic with one formed bowel motion daily, a normal CT scan of the abdomen and negative octreotide scan. No changes in body weight or height after surgery were noted (weight, 69 kg; height, 1.65 m). Random blood glucose levels before and after surgery were also not different (6.2 and 5.4 mm, respectively).

**Sample collection**

Blood samples from the patient were collected by venipuncture into a 10% volume of Trasylo1:EDTA:Diprotin A [5000 kallikrein-inhibitory units/ml (a general protease inhibitor; Miles Canada, Etobicoke, Canada): 1.2 mg/ml: 0.1 mM [an inhibitor of dipeptidylpeptidase activity (6); (Sigma, St. Louis, MO)]. Plasma was collected by centrifugation, and stored at −70 C. After resection, the tumor was also stored at −70 C.

**Immunohistochemistry**

For electron microscopy, small pieces of the tumor were fixed in 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide, dehydrated in graded ethanol, processed through propylene oxide, and embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate and examined using a Philips CM 100 electron microscope, as previously described (22).

For immunohistochemistry, tumor pieces were fixed in formalin and embedded in paraffin. Sections were immunostained for adrenocorticotropic hormone, a-subunit, calcitonin, calcitonin gene-related peptide, cholecystokinin, chromogranin, CRH, β-endorphin, enkephalin, gastrin, gial fibrillary acidic protein, GLP-1, GLP-2, glucagon, GHRIH, insulin, neurofilaments, pancreatic polypeptide, PY, S100, secretin, serotonin, somatostatin, synaptophysin, tyrosine hydroxylase and vasoactive intestinal peptide, as previously described (23). The immunostaining was detected with the streptavidin-biotin-peroxidase complex technique.

**Northern blot analysis**

Pieces of tumor from opposite ends of the mass were extracted in guanidium isothiocyanate for Northern blot analysis. Blots were probed using cDNA probes for proglucagon, proPYY, pro-cholecystokinin and 18SrRNA, as described (24–27). As positive controls, RNA from secretin tumor cell (STC-1) and glucagon-SV40-large T antigen (GLUTag) cells (both derived from mouse enteroendocrine tumors), and InR1-G9 cells (a hamster pancreatic islet A cell line), was also analyzed by Northern blot, as previously reported (26, 27).

![Fig. 1. Schematic of proglucagon and the proglucagon-derived peptides. Posttranslational processing in the pancreas liberates glucagon, whereas intestinal-specific processing results in the biosynthesis of glicentin, oxyntomodulin, GLP-1, and GLP-2 (GRPP, glicentin-related pancreatic peptide; MPGF, major proglucagon fragment). Recognition sites for antisera used in RIAs are indicated: - , GLI; •, IRG; ○, GLP-136NH2; ●, GLP-2.](image)

![Fig. 2. Levels of immunoreactive proglucagon-derived peptides in plasma and the tumor. Samples were assayed for enteroglucagon (glicentin + oxyntomodulin), IRG (pancreatic glucagon), GLP-136NH2 and mid-sequence GLP-2, and data are expressed as nanograms per milliliter for plasma and nanograms per microgram protein for the tumor.](image)
Peptide analysis

Peptides in plasma and in a section of tumor were extracted by reversed-phase adsorption to a C18 silica Sep Pak (Waters Associates, Milford, MA), as previously reported (3, 6). Glicentin, oxyntomodulin, and glucagon were separated by reversed-phase HPLC on a C18 μBondapak column (Waters Associates), using a gradient of 25-62.5% solvent B [solvent A = 1% TFA (pH adjusted to 2.5 with diethylamine); solvent B = 80% acetonitrile] (3, 27, 28). Different forms of GLP-1 were separated by HPLC using a gradient of 45–68% solvent A (solvent A = 0.1% H3PO4 and 0.3% triethylamine; solvent B = 80% solvent A and 60% acetonitrile) (3, 27, 28). GLP-2 and related peptides were separated by HPLC using a gradient of 30–60% solvent B (solvent A = 0.1% TFA in water; solvent B = 0.1% TFA in acetonitrile) (3, 6). All fractions were dried in vacuo before RIA.

Peptides were measured by RIA, as previously described (3, 6, 27, 28). The antigenic sites recognized by each antiserum are indicated in Fig. 1. In brief, RIA for glucagon-like immunoreactivity (GLI; glicentin, oxyntomodulin and glucagon) was carried out using antisera K4023 ( Biospecific, Emeryville, CA), whereas RIA for immunoreactive glucagon (IRG) was conducted using antiserum 04A (Dr. R. Unger, Dallas, TX); synthetic glucagon1–29 was used as the standard for both RIAs. In the same plasma samples, the difference between GLI and IRG represents enteroglucagon (e.g. glicentin + oxyntomodulin). RIA for GLP-1 was conducted using antiserum GLP-17–36NH2 ( Affinity Research Products Ltd., Mamhead, UK), which recognizes the C-terminal sequence of GLP-1, including both biologically active and inactive forms of the peptide, and synthetic GLP-17–36NH2 as the standard. RIA for GLP-2 was conducted using an antiserum (UTTH-7) that recognizes the mid-sequence of both biologically active and inactive forms of GLP-2, and synthetic GLP-21–35 was used as the standard.

Results

Characterization of plasma proglucagon-derived peptides

Plasma levels of enteroglucagon (glicentin + oxyntomodulin), glucagon, GLP-1 and GLP-2 were found to be 6.87, 0.33, 1.01, and 11.23 nmol/liter, respectively, in the patient (Fig. 2). These levels were 10- to 400-fold greater than those found in normal fasting humans (range = 7–35 pmol/liter (5, 6). HPLC analysis of the plasma (Fig. 3) demonstrated the presence of oxyntomodulin and glucagon, as well as the biologically active GLP-17–36NH2 and GLP-11–33. An inactive metabolite of GLP-2, GLP-23–33, was also detected in the plasma, consistent with studies in normal humans (6). No immunoreactive peptide could be found eluting in the position as glicentin, although a number of unidentified peaks of GLI were observed with retention times shorter than those of the known proglucagon-derived peptides that are detectable with this assay. No immunoreactive peptide was detected eluting with the same retention time as proglucagon.

Tumor histology and characterization of proglucagon-derived peptides

The tumor was highly vascularized with widespread angioinvasion. The cells were epithelial in morphology, with moderate-to-abundant pink cytoplasm and bland nuclei with finely dispersed chromat and occasional inconspicuous nucleoli and areas of differentiation with small cell morphology (Fig. 4A). Electron microscopy revealed moderately to well differentiated endocrine cells with well-developed endoplasmic reticulum and Golgi complexes, as well as numerous round secretory granules of variable size and electron density. Immunohistochemical analysis revealed the presence of immunoreactivity for synaptophysin (Fig. 4B), GLP-1 (Fig. 4C) and GLP-2 (Fig. 4D), as well as PYY and pancreatic polypeptide (not shown). The cells were negative for all other markers tested.

Northern blot analysis of the tumor revealed the presence of mRNA transcripts for proglucagon and PYY, but not cho-
lecystokinin (Fig. 5). Proglucagon mRNA transcripts were also detected in STC-1, GLUTag, and InR1-G9 cells, and cholecystokinin, but not PYY, mRNA was found in the STC-1 and GLUTag enteroendocrine cell lines, consistent with previous reports (27, 28).

Consistent with the elevated plasma levels of proglucagon-derived peptides in the patient, enteroglucagon (glicentin + oxyntomodulin), IRG, GLP-1, and GLP-2 were all detected in a sample of the tumor (0.16, 0.04, 0.18, and 2.79 nmol/mg protein, respectively; Fig. 2). HPLC analysis of the tumor sample revealed an intestinal profile of proglucagon processing, with significant peaks of immunoreactivity eluting with the same retention times as oxyntomodulin and GLP-1<sup>7-36NH<sub>2</sub></sup>; no peaks of glicentin or glucagon were detected (Fig. 6). HPLC analysis of the GLP-2-related peptides revealed the presence of three main peaks, the first of which corresponded to the elution position of synthetic GLP-2<sup>1-33</sup>; the identity of the other two peaks remains to be established.

**Discussion**

This report describes a patient with a proglucagon-expressing tumor that secreted an intestinal profile of proglucagon-derived peptides in association with prolonged gastric emptying, delayed small intestinal transit and intractable constipation; these abnormalities were fully reversed after complete resection of the tumor. These findings are consistent with and extend an earlier report describing a patient with an enteroglucagonoma and severe constipation (20, 21) and are in accord with the delayed intestinal transit described recently in one additional patient, who succumbed to a metastatic neuroendocrine tumor also producing GLP-1, GLP-2, and PYY (29). Thus, elevated circulating levels of GLP-1, GLP-2, and/or PYY appear to be associated with marked prolongation of gastric emptying and small and large intestinal motor activity. These findings are also consistent with studies conducted in experimental animal models demonstrating roles for all three of these peptides in the regulation of gastrointestinal motility (1, 7, 9–15).

The levels of both GLP-1 and GLP-2 were elevated by 300- to 400-fold in the patient compared with normal fasting humans (5, 6). However, plasma GLP-2 concentrations were higher than those of GLP-1 in the patient, which may reflect
either the relatively greater levels of GLP-2 contained within the tumor, or different rates of clearance of the two peptides in the circulation (30, 31). It has been reported that GLP-2 has similar potency to GLP-1 in the inhibition of hypoglycemia-induced antral motility in pigs (11). However, in humans, administration of identical doses (4–5 nmol/kg body weight) of GLP-1 (16) or GLP-2 (32) has been reported to cause nausea and gastrointestinal discomfort only in the patients receiving GLP-1. These results therefore suggest that GLP-1 may be more potent than GLP-2 in the suppression of gastrointestinal motility in humans.

The processing of proglucagon in the tumor was found to be similar to that of the normal intestinal L cell, leading to production of oxyntomodulin, GLP-1 and GLP-2. It was somewhat unexpected, however, that the tumor did not contain any glicentin. Proglucagon processing in the L cell is mediated by the enzyme prohormone convertase 1 (3). As oxyntomodulin may be synthesized by secondary processing of glicentin (Fig. 1), the lack of tumor-associated glicentin suggests that either glicentin was rapidly generated and secreted, or proglucagon processing in this tumor by PC1 was more efficient than that normally found in the L cell, resulting in the cleavage of glicentin to form oxyntomodulin. Altered proglucagon processing in endocrine L cell tumors has also previously been noted in transgenic mice harboring proglucagon-producing intestinal tumors (27, 33), although in those tumors, aberrant production of pancreatic-type glucagon was found to occur.

Although the present tumor did not contain any glucagon, slightly elevated levels of glucagon were found in the circulation. Similarly, the proportion of circulating oxyntomodulin was also markedly elevated compared with that in the tumor (Fig. 2). These findings suggest that the secretion of glucagon and oxyntomodulin was increased in this patient and/or their clearance from the circulation may have been reduced. Inappropriately elevated plasma levels of glucagon were also noted in the first reported patient with an enteroglucagonoma (20, 21), indicating that this may be a common feature of such tumors.

The tumor was found to contain mRNA transcripts for PYY, and immunoreactive PYY was detected by immunohistochemical analysis of tumor sections. These findings were not unexpected, as PYY has been colocalized to the same intestinal L cells that produce GLP-1 and GLP-2 (34). Furthermore, these peptides appear to be cosecreted by the normal L cell (35). Additionally, it is well known that de-differentiated gastroenteropancreatic endocrine cell tumors are often plurihormonal in nature (36).

In addition to its effects on intestinal transit, GLP-2 has been found to be an intestinal growth factor (17–19). Administration of GLP-2 to normal rodents for 10 d stimulates marked increases in small and large bowel wet weight. This growth occurs concomitant to increased crypt cell proliferation and decreased villus cell apoptosis (19, 37) and leads to an increased capacity for nutrient digestion and absorption (38). Consistent with these findings, small intestinal biopsies from other patients with enteroglucagonomas have shown the presence of elongated villi (20, 21, 29, 39). It was not possible to obtain small intestinal biopsies from the present patient; however, enlarged mucosal folds were noted during a small bowel follow-through. In contrast, the epithelial hyperplasia found in colonic biopsies were consistent with reactive changes secondary to colonic stasis; hence, it is difficult to ascribe a specific role to one or more of the tumor-derived peptides in the regulation of large bowel mucosal epithelial proliferation.
Finally, the recent report of another patient with an un-
resectable GLP-1- and GLP-2-producing tumor (29) provides
some opportunity for comparison with the present patient.
In the other patient, circulating levels of GLP-1 and GLP-2
were found to be 0.24 and 0.82 nmol/liter, respectively, and
the patient was reported to move his bowels weekly, un-
aided. By contrast, in our patient, plasma levels of these
peptides were 4- to 14-fold greater (1.01 and 11.23 nmol/liter,
respectively), and the patient moved her bowels bimonthly,
and then, only with the use of potent laxatives or enemas.
Because the tumor was amenable to complete resection in our
patient, her symptoms fully abated postoperatively. Thus, in
these two patients, there appears to be a relationship between
the magnitude of circulating levels of the GLPs and the
severity of the motility impairment. Consistent with this
suggestion, a dose-dependent relationship has been reported
between GLP-1 and gastric symptoms (nausea and vomiting)
in normal human volunteers (16).

In summary, the results of the present study provide ev-
idence of roles for GLP-1 and GLP-2 in the regulation of the
ileal brake and in colonic motor activity, whereby overex-
pression of these intestinal hormones leads to marked gas-
trintestinal stasis. It remains to be established whether these
peptides may also contribute to other clinical conditions as-
associated with either impaired or enhanced intestinal motility.

Acknowledgments

Received January 10, 2002. Accepted April 11, 2002.
Address all correspondence and requests for reprints to: Dr. P. L.
Brubaker, Room 3366 Medical Sciences Building, University of Toronto,
1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada. E-mail:
p.brubaker@utoronto.ca.

This work was supported by grants from the Canadian Institutes of
Health Research (to P.L.B. and D.J.D.), the Crohn’s and Colitis Foun-
dation of Canada (to P.L.B.) and the National Cancer Institute of
Canada (D.J.D.). D.J.D. is a Senior Scientist of the CIHR, and P.L.B. is
supported by the Canada Research Chairs Program.

References

Curr Gastroenterol Rep 1:404–409
2. Fujiyama M, Inui A 2000 Peptidergic regulation of gastrointestinal motility in
rodents. Peptides 21:1563–1582
3. Dhanvantari S, Seidah NG, Brubaker PL 1996 Role of prohormone convertases
in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342–355
RH 1987 Peptide YY: structure of the precursor and expression in exocrine
and reactive hypoglycemia after partial gastrectomy. Digestion 55:221–228
6. Xiao Q, Boushey R, Drucker DJ, Brubaker PL 1999 Secretion of the intesti-
notropic hormone glucagon-like peptide-2 is differentially regulated by nu-
trients in humans. Gastroenterology 117:99–105
7. Spiller RC, Trotman IJ, Adrian TE, Bloom SR, Misiewicz JJ, Silk DBA 1988
Further characterization of the ileal brake reflex in man: effect of ileal infusion
of partial digests of fat, protein, and starch on jejunal motility and release of
neurotensin, enteroglucagon, and peptide YY. Gut 29:1042–1051
8. Dummovin V, Moro F, Barcelo A, Dakka T, CuberJC 1998 Peptide YY,
glucagon-like peptide-1, and neurotensin responses to luminal factors in the
isolated vascularly perfused rat ileum. Endocrinology 139:3780–3786
9. Armstrong CA, Daniel EE, McDonald TJ 1998 Effects of GLP-1 on
gastric emptying, antypyloric motility, and transpyloric flow in response to
effect 1 retards gastric emptying and small bowel transit in the rat—effect
mediated through central or enteric nervous mechanisms. Dig Dis Sci 43:
2284–2290
peptide-2 inhibits centrally induced antral motility in pigs. Scan J Gastro-
enterol 33:828–832
effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed
motility inhibited via nitric oxide independent of insulin and somatostatin.
J Clin Invest 102:764–774
brake induced by intraluminal peptides in rat. Dig Dis Sci 44:322–329
e, Tosetti C, Poggioli G, Morselli Labate AM, Monetti N, Gozzetti G, Barbara
L, Go VLW 1993 Fat-induced ileal brake in humans: a dose-dependent phe-
nomenon correlated to the plasma levels of peptide YY. Gastroenterology 105:725–729
dog depends on peptide YY. Gastroenterology 110:1491–1495
and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous
injection in healthy volunteers. Dose-response relationships. Diabetologia 38:
720–725
876–913
epithelial proliferation by glucagon-like peptide-2. Proc Natl Acad Sci USA
93:7911–7916
tumour in kidney affecting small bowel structure, motility, and absorptive
growth hormone (GH) autoregulation in pituitary somatotrophs in GH an-
tagonist-transgenic mice and GH-receptor deficient mice. Am J Pathol 156:
1009–1015
L, Asa SL, Drucker DJ 2000 Enteroneuroendocrine localization of GLP-2 receptor
24. Brubaker PL, Drucker DJ, Asa SL, Greenberg GR 1991 Regulation of pep-
tide YY synthesis and secretion in fetal rat intestinal cultures. Endocrinology
129:3351–3358
25. Ehrlich P, Tucker D, Asa SL, Brubaker PL, Drucker DJ 1994 Inhibition of
pancreatic proglucagon gene expression in mice bearing subcutaneous endo-
proglucagon gene promoters in vivo. Am J Physiol: Gastrointest Liver Physiol
277:G829–G837
27. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL 1994 Activation of
proglucagon gene transcription by protein kinase A in a novel mouse
enteroendocrine cell line. Mol Endocrinol 8:1646–1655
28. Tucker JD, Dhanvantari S, Brubaker PL 1996 Proglucagon processing in islet
and intestinal cell lines. Regul Pept 62:299–305
Intestinal proliferation and delayed intestinal transit in a patient with a GLP-1,
GLP-2, and PYY-producing neuroendocrine carcinoma. Digestion 63:61–68
30. Tavares W, Drucker DJ, Brubaker PL 2000 Enzymatic- and renal-dependent
catabolism of the intestino-pancreatic glucagon-like peptide-2 in rats. Am
J Physiol: Endocrinol Metab 278:E134–E139
of glucagon-like peptide-1 7–36 amide and glucagon-like peptide-1 7–37 in
healthy subjects are indistinguishable. Diabetes 42:658–661
32. Hartmann B, Harr MB, Jeppesen PB, Wiedemann M, Deacon CF, Mortensen
in humans. J Clin Endocrinol Metab 85:2284–2288
33. Brubaker PL, Lee YC, Drucker DJ 1992 Alterations in proglucagon processing
and inhibition of proglucagon gene expression in transgenic mice which con-
1992 Glucagon-like peptide-1 retards gastric emptying and small bowel transit in
the rat—effect mediated through central or enteric nervous mechanisms. Dig Dis
Sci 43:2284–2290
35. Stevens FM, Flanagan RW, O’Gorman D, Buchanann KD 1984 Glucagonoma
syndrome demonstrating giant duodenal villi. Gut 25:784–791